Nektar Therapeutics share price logo

Nektar Therapeutics Share Price

NASDAQ: NKTR

Small Cap

$58.77

+7.70

(+15.09%)

as on

Nektar Therapeutics Stock Performance

as on September 19, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $52.13
    $58.74
    downward going graph

    11.30%

    Downside

    -0.05%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $6.48
    $52.75
    downward going graph

    88.97%

    Downside

    -10.24%

    Upside

    downward going graph

Nektar Therapeutics share price movements today

Previous Close
$51.07
Open
$55.61
Volume
1.6M
Day's Low - High
$52.13 - $58.74
52 Week Low - High
$6.48 - $52.75

Nektar Therapeutics Historical Returns

1 Month Return
+ 86.18 %
3 Month Return
+ 493.15 %
1 Year Return
+ 170.21 %
3 Year Return
-1.88 %
5 Year Return
-83.12 %

Nektar Therapeutics Stock Fundamentals & Key Indicators

Check Nektar Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$971.3M

EPS (TTM)

-11.0633

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.32

Industry PE ratio

-3.9415151515151514

P/B Ratio

0

PEG Ratio

3.22

EBITDA

-137.2M

Revenue (TTM)

74.9M

Profit Margin

-163.17%

Return On Equity TTM

6206900.00%

Nektar Therapeutics Stock Valuation

Track how Nektar Therapeutics P/E has moved over time to understand its valuation trends.

Nektar Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 18, 2025

Industry (-3.94x)

September 18, 2025

Today (-1.32x)

September 18, 2025

Highest (0.00x)

September 18, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.32x

Nektar Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Nektar Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
HOLD$971.3M-83.12%-1.32-163.17%
BUY$60.5B241.54%-505.15-12.96%
NA$38.7BNANA-3.89%
BUY$99.3B45.88%27.5631.86%
BUY$60.9B5.45%14.4931.37%

Stock Returns calculator for Nektar Therapeutics Stock including INR - Dollar returns

The Nektar Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Nektar Therapeutics investment value today

Current value as on today

₹3,15,906

Returns

₹2,15,906

(+215.91%)

Returns from Nektar Therapeutics Stock

₹2,10,952 (+210.95%)

Dollar Returns*

₹4,953 (+4.95%)

Analyst Recommendation on Nektar Therapeutics Stock

Based on 9 analysts

HOLD

0.00%

Buy

55.56%

Hold

44.44%

Sell

Based on 9 analysts, 55.56% of analysts recommend a 'HOLD' rating for Nektar Therapeutics. Average target price of $96.17

Nektar Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Nektar Therapeutics.

What analysts predicted

38.89%UPSIDE

Target Price

$96.17

Current Price

$58.77

Analyzed by

9 Analysts

Target

$96.17

Nektar Therapeutics target price $96.17, a slight upside of 38.89% compared to current price of $58.77. According to 9 analysts rating.

Nektar Therapeutics Stock's Interest Amongst Investors

Search interest for Nektar Therapeutics Stock has increased by 68% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:68% versus previous 30 day period

Nektar Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
21
20
24
23
21
23
24
29
10
11
Gross Profit
14
13
11
16
13
13
19
21
10
10
Operating Income
-134
-50
-33
92
-35
-49
-34
14
-44
-36
EBITDA
-128
-42
-38
-33
-29
-44
-30
17
-40
-36
Interest Expense
6
6
5
6
5
6
6
10
4
5
Depreciation
2
2
1
1
1
1
0
0
0
0
Income Before Tax
-137
-51
-45
-42
-36
-52
-37
7
-46
-39
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-137
-51
-45
-42
-36
-52
-37
7
-50
-41
Net Profit Margin
-634.52%
-249.39%
-189.85%
-176.17%
-170.07%
-222.93%
-153.61%
24.89%
-486.44%
-372.20%

Nektar Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
230
165
307
1,193
114
152
101
92
90
98
Gross Profit
196
135
277
1,168
93
133
77
70
53
67
Operating Income
-29
-112
-59
687
-440
-379
-446
-240
-137
-105
EBITDA
-29
-97
-42
734
-382
-394
-462
-323
-243
-86
Interest Expense
38
42
40
42
46
37
47
28
25
28
Depreciation
-
-
14
10
13
14
14
13
9
4
Income Before Tax
-80
-152
-96
682
-440
-443
-523
-364
-276
-119
Income Tax Expense
0
0
0
1
0
0
0
3
0
0
Net Income
-81
-153
-96
681
-440
-444
-523
-368
-276
-118
Net Profit Margin
-35.17%
-92.80%
-31.42%
57.09%
-384.47%
-290.65%
-514.03%
-399.98%
-306.31%
-120.86%

Nektar Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-51
-45
-42
-36
-52
-37
7
-50
-41
Operating Cash Flow
-51
-42
-47
-47
-37
-43
-46
-49
-45
Investing Cash Flow
25
56
17
19
16
46
60
43
49
Financing Cash Flow
0
-64
0
42
0
0
0
0
0
Change in Cash
-26
-50
-29
14
-20
2
14
-5
4

Nektar Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-153
-96
681
-440
-444
-523
-368
-276
-118
Operating Cash Flow
-117
-80
718
-328
-313
-412
-304
-192
-175
Investing Cash Flow
-82
-28
-1,379
206
496
202
365
139
142
Financing Cash Flow
203
54
851
23
-80
36
1
0
42
Change in Cash
4
-54
190
-98
102
-173
63
-52
8

Global Institutional Holdings in Nektar Therapeutics

Funds
Holdings
BlackRock Inc
6.05%
Vanguard Group Inc
4.74%
Nantahala Capital Management, LLC
3%
Acadian Asset Management LLC
2.81%
Eventide Asset Management, LLC
2.56%

Insights on Nektar Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, NKTR stock has moved up by 493.1%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -50.88M → -41.59M (in $), with an average increase of 22.3% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 10.46M → 11.17M (in $), with an average increase of 6.4% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, NKTR has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 113.4%

About Nektar Therapeutics

nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
OrganisationNektar Therapeutics
Headquarters455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
IndustryHealth Technology
CEOMr. Howard W. Robin
E-voting on sharesClick here to vote

Key Management of Nektar Therapeutics

Name

Title

Mr. Howard W. Robin

CEO, President & Director

Ms. Sandra A. Gardiner

CFO and Principal Financial & Accounting Officer

Mr. Mark A. Wilson J.D.

Senior VP, Chief Legal Officer & Secretary

Dr. Jonathan Zalevsky Ph.D.

Senior VP and Chief Research & Development Officer

Mr. Jason Barnard

Chief Accounting Officer

Mr. Robert Bacci

Chief People Officer and Head of Quality & Facilities

Ms. Jennifer Ruddock

Chief Business Officer

Dr. Brian L. Kotzin M.D.

Interim Chief Medical Officer

FAQs

What is Nektar Therapeutics share price today?

Nektar Therapeutics share price today is $58.77 as on at the close of the market. Nektar Therapeutics share today touched a day high of $58.74 and a low of $52.13.

What is the 52 week high and 52 week low for Nektar Therapeutics share?

Nektar Therapeutics share touched a 52 week high of $52.75 on and a 52 week low of $6.48 on . Nektar Therapeutics stock price today i.e. is closed at $58.77,which is -11.41% down from its 52 week high and 806.94% up from its 52 week low.

What is Nektar Therapeutics's market capitalisation today?

Nektar Therapeutics market capitalisation is $0.00T as on .

How to invest in Nektar Therapeutics Stock (NKTR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Nektar Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Nektar Therapeutics Shares that will get you 0.0255 shares as per Nektar Therapeutics share price of $58.77 per share as on September 19, 2025 at 1:29 am IST.

What is the minimum amount required to buy Nektar Therapeutics Stock (NKTR) from India?

Indian investors can start investing in Nektar Therapeutics (NKTR) shares with as little as ₹88.114 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Nektar Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Nektar Therapeutics share’s latest price of $58.77 as on September 19, 2025 at 1:29 am IST, you will get 0.1702 shares of Nektar Therapeutics. Learn more about fractional shares .

What are the returns that Nektar Therapeutics has given to Indian investors in the last 5 years?

Nektar Therapeutics stock has given -83.12% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?